Compounded GLP-1 Advertising: What Clinics Can Say

What NAD Actually Decided in the Willow Health Case

The National Advertising Division is part of BBB National Programs. It runs the advertising industry's self-regulatory process: a competitor or other party can challenge an advertiser's claims, NAD reviews the substantiation, and it issues a recommendation. NAD has no government enforcement power of its own, but it has a long-standing referral relationship with the FTC, and regulators take its referrals seriously.

In the Willow Health matter, Novo Nordisk, the maker of branded semaglutide products, challenged the way Willow advertised its compounded semaglutide. On December 4, 2025, NAD recommended that Willow discontinue claims framing the compounded product as superior to, or as safe and effective as, the approved branded version. Willow declined to comply with the recommendation. NAD then referred the matter to the appropriate regulators for further review.

The reason this is worth your attention is not the company involved. It is the principle. NAD's position establishes an early self-regulatory precedent that you cannot take the clinical evidence developed for an FDA-approved drug and use it to advertise a compounded version as if that evidence applies. Compounded products are not FDA-approved. They have not been through the same review for safety, efficacy, and manufacturing quality that the branded product cleared. So the branded drug's data is not your data, and borrowing it to imply equivalence is exactly the move NAD flagged.

Why "Borrowing the Brand's Claims" Is the Core Problem

It is easy to see how a clinic ends up over the line without intending to. The branded drug has years of trial data, a recognizable name, and a clear efficacy story. The compounded version contains the same active ingredient. The marketing shortcut writes itself: same molecule, same results, lower price.

That shortcut is the trap. The active ingredient being similar does not make the products legally interchangeable for advertising purposes. The branded product earned its efficacy and safety claims through a specific FDA review. The compounded product did not go through that review, so it does not inherit those claims. When your ad implies it does, whether by direct comparison, by citing the brand's trial outcomes, or by suggesting equivalence, you are making a claim your specific product cannot substantiate.

The throughline, and the single sentence worth pinning above your marketing calendar, is this: claims must match the evidence for the specific product you are selling. Not the molecule. Not the branded cousin. The product in your patient's hands.

A Practical Reference: What You Can and Cannot Say

The table below translates the precedent into a working reference for clinic operators. It is a starting point for a conversation with your counsel, not a substitute for that conversation. Your specific claims, state, and product all change the analysis.

|---|---|---|

Two patterns are worth calling out from that table. First, avoid anything that implies FDA approval or equivalence to the branded drug, because the compounded product has neither. Second, hold substantiation for every claim you do make, and keep it tied to the specific product, because "we believe it works" is not substantiation, and the brand's trial is not your trial.

How This Fits the Broader 2026 Enforcement Environment

The Willow decision does not sit in isolation. Through 2025 and into 2026, the regulatory environment around compounded GLP-1 marketing has tightened. The FDA has issued warning letters to telehealth marketers over how compounded products were advertised, and the FTC has shown interest in the space. We are describing a direction of travel here, not predicting any specific outcome, so it is worth being precise: the consistent message across these actions is the same one NAD articulated. Claims have to match the evidence for the specific product being sold.

For a clinic operator, the practical implication is that self-regulatory bodies and government regulators are looking at the same behavior from different angles. A NAD referral can reach the FTC. State Attorneys General have their own consumer-protection authority. The safest posture is not to find the narrowest path around a single decision, but to adopt the underlying principle as a standing rule for all of your marketing.

What You Can Do to Stay on the Right Side of the Line

None of this means you cannot market a compounded GLP-1 program. It means the marketing has to be built on what you can actually support. In practical terms, for clinic operators:

For deeper context on the sourcing and prescribing side of a compliant program, see our companion pieces on [compounding pharmacy sourcing for clinics](/blog/clinic-compounding-pharmacy-sourcing) and [telehealth peptide prescribing](/blog/clinic-telehealth-peptide-prescribing).

What to Track: Documentation and Outcomes

Advertising claims are only one half of the exposure. The other half is whether you can show, with records, what your clinic actually did. When a regulator, a payer, or your own counsel asks what was prescribed, to whom, on what basis, and what was monitored, the answer should be a clean record, not a reconstruction from memory and scattered files.

For clinic operators, defensible documentation means keeping a consistent, time-stamped record of each protocol you run and the labs and outcomes tracked alongside it. A few elements that operators commonly keep organized:

This is the angle where a tracking tool earns its place. MyProtocolStack is documentation and tracking infrastructure for your clinic, not a marketing tool and not a substitute for legal review. It gives you a structured, longitudinal record of every protocol and lab so that when a question comes, the answer already exists. You can browse the [semaglutide overview](/peptides/semaglutide) and the broader [peptide library](/peptides) for plain-language reference on the compounds your patients ask about.

[Give your clinic a clean record of every protocol and lab with MyProtocolStack.](/auth/login?mode=signup)

Frequently Asked Questions

Can my clinic advertise compounded semaglutide as "the same as" the branded drug?

No. The December 2025 NAD decision in the Willow Health matter centered on exactly this kind of claim. Compounded products are not FDA-approved and have not been through the same review as the branded drug, so they do not inherit the branded product's safety and efficacy evidence. Implying equivalence is the claim NAD recommended be discontinued. This is general education, not legal advice; confirm your specific marketing with healthcare-regulatory counsel.

What did NAD decide in the Willow Health case?

On December 4, 2025, the BBB National Advertising Division, acting on a challenge by Novo Nordisk, recommended that telehealth company Willow Health discontinue superiority, safety, and efficacy claims for its compounded semaglutide products. Willow declined to comply, and NAD referred the matter to regulators, which can include the FTC and state Attorneys General. It is an early self-regulatory precedent that you cannot borrow an FDA-approved drug's evidence to advertise a compounded version.

Does NAD have the power to fine my clinic?

NAD itself is a self-regulatory body and does not levy government fines. Its power comes from review, public recommendations, and its referral relationship with regulators. When an advertiser declines to comply, as Willow did, NAD can refer the matter to the FTC or state Attorneys General, who do have enforcement authority. The practical risk is the referral and what follows it, not a penalty from NAD directly.

What claims are generally safer to make about a compounded GLP-1 program?

Truthful, substantiated statements about your clinic's service, process, and clinician oversight are generally on firmer ground than product efficacy claims, because they describe what your practice does rather than implying the product carries the branded drug's evidence. Even then, every claim needs substantiation specific to it, appropriate disclaimers, and a review by counsel before it runs. Avoid FDA-approval implications, equivalence claims, and superiority claims entirely.

How does documentation help if a regulator or counsel asks questions?

A clean, time-stamped record of what was prescribed, the basis for it, what was tracked, and what the patient was told lets you answer questions with evidence rather than reconstruction. MyProtocolStack provides that documentation and tracking layer for clinics. It does not provide legal advice, write your marketing, or substitute for review by your own healthcare-regulatory counsel.

Sources

1. BBB National Programs, NAD decision in the Willow Health matter. https://bbbprograms.org/media/newsroom/decisions/willow-health

2. Polsinelli, "NAD Weighs In on Compounded GLP-1 Advertising." https://www.polsinelli.com/publications/nad-compounded-glp-1-advertising-diet

3. Fierce Pharma, "Semaglutide compounder drops claims after Novo Nordisk challenge." https://www.fiercepharma.com/marketing/semaglutide-compounder-drops-claims-after-novo-nordisk-challenge

*This article is general education for clinic operators, not legal advice. Advertising law as applied to compounded products is fact-specific and evolving, and nothing here should be relied on as a legal opinion. Consult your own qualified healthcare-regulatory counsel before publishing any marketing claims. MyProtocolStack is a tracking and education tool, not medical advice, diagnosis, treatment, or a marketing service.*